Skip to main content
. Author manuscript; available in PMC: 2013 Mar 1.
Published in final edited form as: Vet Comp Oncol. 2011 May 18;10(1):44–56. doi: 10.1111/j.1476-5829.2011.00274.x

Figure 1. Certain bisphosphonate and chemotherapy combinations elicit significantly increased killing of canine MH cells in vitro.

Figure 1

In (A), the effects of clodronate on chemotherapy-induced killing of canine DH82 MH cells was assessed, using an MTT assay to assess tumor cell viability. Cells were treated with chemotherapy drug alone (black), clodronate alone (white), or with the combination of clodronate and chemotherapy drug (cross-hatch). In these assays, only the combination of clodronate and vincristine demonstrated a significant positive interaction (* = p < 0.05), as assessed by 1 way ANOVA with Tukey's post test. In (B), the effects of zoledronate on DH82 MH cell sensitivity to killing with chemotherapy drugs were assessed, using a similar approach as for (A). Cells were treated with chemotherapy drugs alone (black), zoledronate alone (white), or the two in combination (cross-hatch). The combination of zoledronate with doxorubicin showed a significant positive interaction (* = p < 0.05), as assessed by 1 way ANOVA with Tukey's post test. Cl = clodronate (5 μg/mL), Dex = dexamethasone (15 μg/mL), Dox = doxorubicin (0.2 μg/mL), CCNU = lomustine (1.5 μg/mL), vinc = vincristine (0.25 μg/mL), z = zoledronate (0.2 μg/mL).